Search filters
Reimbursement Scheme Forxiga® (dapagliflozin) 10 mg for patients with diabetes partially stopped

Reimbursement Scheme Forxiga® (dapagliflozin) 10 mg for patients with diabetes partially stopped

22/09/2021

From September 1st 2021 onwards, Forxiga® (dapagliflozin) 10 mg for the treatment of adults with type 2 diabetes mellitus with a...

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg - Chronic Kidney Disease

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg - Chronic Kidney Disease

11/08/2021

The health insurer does not yet fully reimburse Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney disease...

Termination TerugBetaalRegeling Forxiga® - Hartfalen

Termination TerugBetaalRegeling Forxiga® - Hartfalen

30/06/2021

From July 1st 2021 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of heart failure with reduced ejection fraction...

Amendment to TerugBetaalRegeling Lokelma®

Amendment to TerugBetaalRegeling Lokelma®

19/05/2021

TBR Nederland hereby informs you that it will make a change to a repayment scheme starting from now. This concerns the medicine...

Reimbursement Scheme FRAGMIN® 2500

Reimbursement Scheme FRAGMIN® 2500

28/01/2021

The health insurer does not fully reimburse FRAGMIN® 2500. The producer of this medicine has therefore asked TBR Nederland to...

You are currently offline. Some pages or content may fail to load.